Nepal Says Gavi Will Provide Rs 8.59 Billion in Vaccine Support Through 2030
Gavi will also waive a reported $308,271 repayment demand, but details of the earlier audit and Nepal's future co-financing obligations remain unclear.
KATHMANDU, Nepal — Nepal has secured Rs 8.59 billion in vaccine support from Gavi through 2030, the health ministry said on Tuesday, according to local reports that also described a repayment waiver linked to an audit of earlier immunisation assistance.
The announcement offers a longer funding horizon for routine vaccination while raising a separate question about financial oversight: how the government will address the procedural shortcomings identified in earlier assistance. The reported waiver does not, by itself, establish what corrective measures were required or whether the audit's recommendations have been implemented.
Gavi also agreed to waive $308,271 that Nepal had been asked to repay, according to the minister's secretariat as reported by Onlinekhabar. The Himalayan Times linked that repayment demand to an audit covering assistance provided between fiscal years 2016/17 and 2021/22.
The Himalayan Times' account of the ministry announcement said the audit identified procedural shortcomings in the use of funds. It did not describe the individual findings, identify responsible officials or publish the terms on which repayment was waived.
A waiver of repayment should not be treated as evidence that the audit findings were withdrawn. The available accounts establish a reported financial concession, not a published conclusion about the underlying shortcomings.
Onlinekhabar described the new commitment as vaccines worth Rs 8.59 billion, while The Himalayan Times called it vaccine support. Neither report provided a breakdown distinguishing vaccine purchases, delivery costs or other programme assistance, and the support should not be presented as an unrestricted cash transfer.
The government said the assistance would support the continuity, accessibility and effectiveness of routine immunisation services. The available reports did not specify which vaccines would be covered, the number of doses, delivery schedules or the number of people expected to benefit.
Support through 2030 also does not mean the government will have no domestic financing obligations. Under Gavi's eligibility and transition policy, countries receiving vaccine support are expected to finance a share of the required doses, with their contributions generally increasing as national income grows.
Gavi's policy, updated in July 2026, lists Nepal in its "preparatory transition" category. That classification confirms Nepal's place within Gavi's support framework, but it does not independently verify the amount or terms announced by Nepal's government on Tuesday.
The policy distinguishes eligibility for support from the approval of a particular application. Applications are reviewed by independent specialists in areas including immunisation, health systems, cold-chain logistics and financial management. Nepal's reported commitment therefore needs to be assessed against its own approval documents rather than inferred from general eligibility.
The new agreement, Gavi's confirmation, Nepal's co-financing obligations and the basis for the repayment waiver were not available for review. The delivery timetable, vaccine coverage and measures taken in response to the earlier audit remain unclear.